Peter S. Sándor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter S. Sándor has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Andreas R. Gantenbein
Neurology Outpatient Clinic, RehaClinic Bad Zurzach, Bad Zurzach, Switzerland
2 shared publicationsCharly Gaul
Headache Center, University Essen, Essen, Germany
1 shared publicationEli Alon
Private Pain Practice, Zurich, Switzerland
1 shared publication- Franz Riederer
Department of Neurology, Inselspital, Bern University Hospital University of Bern Bern Switzerland
1 shared publication Jan von Meyenburg
Institute of Neuroradiology, University Hospital Zurich, Zurich, Switzerland
1 shared publicationKonrad Maurer
Institute of Anaesthesiology, University Hospital of Zurich, Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 15 February 2013
- Published by Springer Nature in Pain and Therapy
- Vol. 2 (1) , 49-56
Predictive Value of Lidocaine for Treatment Success of Oxcarbazepine in Patients with Neuropathic Pain Syndrome
Introduction Pharmacotherapy in patients with neuropathic pain syndromes (NPS) can be associated with long periods of trial and error before reaching satisfactory analgesia. The aim of this study was to investigate whether a short intravenous (i.v.) infusion of lidocaine may have a predictive value for the efficacy of oxcarbazepine. Methods In total, 16 consecutive patients with NPS were studied in a prospective, uncontrolled, open-label study design. Each patient received i.v. lidocaine (5 mg/kg) within 30 min followed by a long-term oral oxcarbazepine treatment (900–1,500 mg/day). During an observation period of 28 days, treatment response was documented by a questionnaire including the average daily pain score documented on a numeric rating scale (NRS). Results A total of 6 out of 16 patients (38%) were lidocaine responders (defined as pain reduction >50% during the infusion), and 4 of 16 (25%) were oxcarbazepine responders. In total, 6 out of 16 participants (38%) discontinued oxcarbazepine treatment due to side effects. In an interim analysis predictive value of the lidocaine infusion was low with a Kendall’s tau correlation coefficient of 0.29 and coefficient of determination R2 of 0.119 (95% confidence interval –0.29 to 0.72). As a consequence of this low correlation, the study was discontinued for ethical reasons. Conclusion In conclusion, lidocaine infusion has a low predictive value for effectiveness of oxcarbazepine—if at all.
- 15 February 2013
- Published by Springer Nature in Pain and Therapy
- Vol. 2 (1) , 49-56
Open AccessPredictive Value of Lidocaine for Treatment Success of Oxcarbazepine in Patients with Neuropathic Pain Syndrome
Introduction Pharmacotherapy in patients with neuropathic pain syndromes (NPS) can be associated with long periods of trial and error before reaching satisfactory analgesia. The aim of this study was to investigate whether a short intravenous (i.v.) infusion of lidocaine may have a predictive value for the efficacy of oxcarbazepine. Methods In total, 16 consecutive patients with NPS were studied in a prospective, uncontrolled, open-label study design. Each patient received i.v. lidocaine (5 mg/kg) within 30 min followed by a long-term oral oxcarbazepine treatment (900–1,500 mg/day). During an observation period of 28 days, treatment response was documented by a questionnaire including the average daily pain score documented on a numeric rating scale (NRS). Results A total of 6 out of 16 patients (38%) were lidocaine responders (defined as pain reduction >50% during the infusion), and 4 of 16 (25%) were oxcarbazepine responders. In total, 6 out of 16 participants (38%) discontinued oxcarbazepine treatment due to side effects. In an interim analysis predictive value of the lidocaine infusion was low with a Kendall’s tau correlation coefficient of 0.29 and coefficient of determination R2 of 0.119 (95% confidence interval –0.29 to 0.72). As a consequence of this low correlation, the study was discontinued for ethical reasons. Conclusion In conclusion, lidocaine infusion has a low predictive value for effectiveness of oxcarbazepine—if at all.
- 2 July 2012
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 13 (7) , 517-525
Grey matter changes associated with medication-overuse headache: Correlations with disease related disability and anxiety
Objectives. Medication-overuse headache (MOH) is associated with psychiatric comorbidities. Neurobiological similarities to substance dependence have been suggested. This study investigated grey matter changes, focussing on pain and reward systems. Methods. Using voxel-based morphometry, structural MRIs were compared between 29 patients with both, MOH and migraine, according to International Headache Society criteria, and healthy controls. The Migraine Disability Assessment (MIDAS) score was used. Anxiety and depression were screened for with the Hospital Anxiety and Depression Scale (HADS) and confirmed by a psychiatrist, using the Mini International Neuropsychiatric Interview. Results. Nineteen patients (66%) had a present or past psychiatric disorder, mainly affective (N = 11) and anxiety disorders (N = 8). In all patients a significant increase of grey matter volume (GMV) was found in the periaqueductal grey matter of the midbrain, which correlated positively with the MIDAS and the HADS-anxiety subscale. A GMV increase was found bilaterally in the thalamus, and the ventral striatum. A significant GMV decrease was detected in frontal regions including orbitofrontal cortex, anterior cingulate cortex, the left and right insula, and the precuneus. Conclusion. These findings are consistent with dysfunction of antinociceptive systems in MOH, which is influenced by anxiety. Dysfunction of the reward system may be a neurobiological basis for dependence in a subgroup of MOH patients.
- 2 July 2012
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 13 (7) , 517-525
Grey matter changes associated with medication-overuse headache: Correlations with disease related disability and anxiety
Objectives. Medication-overuse headache (MOH) is associated with psychiatric comorbidities. Neurobiological similarities to substance dependence have been suggested. This study investigated grey matter changes, focussing on pain and reward systems. Methods. Using voxel-based morphometry, structural MRIs were compared between 29 patients with both, MOH and migraine, according to International Headache Society criteria, and healthy controls. The Migraine Disability Assessment (MIDAS) score was used. Anxiety and depression were screened for with the Hospital Anxiety and Depression Scale (HADS) and confirmed by a psychiatrist, using the Mini International Neuropsychiatric Interview. Results. Nineteen patients (66%) had a present or past psychiatric disorder, mainly affective (N = 11) and anxiety disorders (N = 8). In all patients a significant increase of grey matter volume (GMV) was found in the periaqueductal grey matter of the midbrain, which correlated positively with the MIDAS and the HADS-anxiety subscale. A GMV increase was found bilaterally in the thalamus, and the ventral striatum. A significant GMV decrease was detected in frontal regions including orbitofrontal cortex, anterior cingulate cortex, the left and right insula, and the precuneus. Conclusion. These findings are consistent with dysfunction of antinociceptive systems in MOH, which is influenced by anxiety. Dysfunction of the reward system may be a neurobiological basis for dependence in a subgroup of MOH patients.